Please login to the form below

Not currently logged in
Email:
Password:

Boehringer Ingelheim's Dr Susan Anton joins Icon

The CRO also appoints Dr Pui Leung, boosting its early phase and epidemiology and risk management teams

Icon has appointed former Boehringer Ingelheim director Dr Susan Anton to head up its epidemiology and risk management practice.

The move is one of two senior appointments at the contract research organisation (CRO), which also see Dr Pui Leung join at a senior clinical research physician.

Dr Anton has more than 25 years of experience leading international epidemiologic, health economic, and outcomes research, and other market access initiatives.

Most recently she served as director of US medical outcomes research and registries at Boehringer Ingelheim, and prior to that directed health economic, epidemiologic and outcomes research efforts across therapeutic areas at Bristol-Myers Squibb.

Meanwhile, Dr Leung, who will be based at Icon's clinical pharmacology unit in Manchester, UK, has 10 years of experience as a senior phase I clinical research physician in two UK CROs.

Before joining the pharmaceutical industry in 2002, he spent 13 years as a hospital physician in the UK's National Health Service (NHS).

22nd May 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Article: What's next? How behavioural science can support pharma's future
...
Video: UX/ Experience design research
...

Infographics